![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Ann Arbor, Michigan (J.A.W, S.H., T.C.G., V.P., J.R.K., S.E.B.), and Sandwich, Kent, United Kingdom (R.H., B.C.G., D.A.S.)
Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs. The objective of this article is to encourage those studying ligand interactions with UDP-glucuronosyltransferases (UGTs) to adequately consider the potential consequences of in vitro UGT inhibition in humans. Spurred on by interest in developing potent and selective inhibitors for improved confidence around UGT reaction phenotyping, and the increased availability of recombinant forms of human UGTs, several recent studies have reported in vitro inhibition of UGT enzymes. In some cases, the observed potency of UGT inhibitors in vitro has been interpreted as having potential relevance in humans via pharmacokinetic drug-drug interactions. Although there are reported examples of clinically relevant drug-drug interactions for UGT substrates, exposure increases of the aglycone are rarely greater than 100% in the presence of an inhibitor relative to its absence (i.e., AUCi/AUC 
2). This small magnitude in change is in contrast to drugs primarily cleared by cytochrome P450 enzymes, where exposures have been reported to increase as much as 35-fold on coadministration with an inhibitor (e.g., ketoconazole inhibition of CYP3A4-catalyzed terfenadine metabolism). In this article the evidence for purported clinical relevance of potent in vitro inhibition of UGT enzymes will be assessed, taking the following into account: in vitro data on the enzymology of glucuronide formation from aglycone, pharmacokinetic principles based on empirical data for inhibition of metabolism, and clinical data on the pharmacokinetic drug-drug interactions of drugs primarily cleared by glucuronidation.
This article has been cited by other articles:
|
|
 |
|
  J. C. Stevens, S. A. Marsh, M. J. Zaya, K. J. Regina, K. Divakaran, M. Le, and R. N. Hines Developmental Changes in Human Liver CYP2D6 Expression Drug Metab. Dispos., August 1, 2008; 36(8): 1587 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yasuda, A. Ranade, R. Venkataramanan, S. Strom, J. Chupka, S. Ekins, E. Schuetz, and K. Bachmann A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine Drug Metab. Dispos., August 1, 2008; 36(8): 1689 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities Drug Metab. Dispos., June 1, 2008; 36(6): 1056 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Kramer, A. E. Rettie, M. J. Rieder, E. T. Cabacungan, and R. N. Hines Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression Mol. Pharmacol., June 1, 2008; 73(6): 1751 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Sohl, E. M. Isin, R. L. Eoff, G. A. Marsch, D. F. Stec, and F. P. Guengerich Cooperativity in Oxidation Reactions Catalyzed by Cytochrome P450 1A2: HIGHLY COOPERATIVE PYRENE HYDROXYLATION AND MULTIPHASIC KINETICS OF LIGAND BINDING J. Biol. Chem., March 14, 2008; 283(11): 7293 - 7308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates Drug Metab. Dispos., February 1, 2008; 36(2): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Miyagi and A. C. Collier Pediatric Development of Glucuronidation: The Ontogeny of Hepatic UGT1A4 Drug Metab. Dispos., September 1, 2007; 35(9): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kassahun, I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L. A. Wenning Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme Drug Metab. Dispos., September 1, 2007; 35(9): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams, and C.-M. Loi Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid Drug Metab. Dispos., August 1, 2007; 35(8): 1315 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rowland, P. Gaganis, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wen, M. N. Tallman, S. Y. Ali, and P. C. Smith UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics Drug Metab. Dispos., March 1, 2007; 35(3): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wen, D. E. Martin, P. Bullock, K.-H. Lee, and P. C. Smith Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences Drug Metab. Dispos., March 1, 2007; 35(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-F. Krippendorff, P. Lienau, A. Reichel, and W. Huisinga Optimizing Classification of Drug-Drug Interaction Potential for CYP450 Isoenzyme Inhibition Assays in Early Drug Discovery J Biomol Screen, February 1, 2007; 12(1): 92 - 99. [Abstract] [PDF]
|
|
|
|
|
|
S. W. J. Wang, J. Chen, X. Jia, V. H. Tam, and M. Hu Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties Drug Metab. Dispos., November 1, 2006; 34(11): 1837 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kumar, D. A. Rock, C. J. Warren, T. S. Tracy, and J. L. Wahlstrom Enzyme Source Effects on CYP2C9 Kinetics and Inhibition Drug Metab. Dispos., November 1, 2006; 34(11): 1903 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. P. Guengerich A malleable catalyst dominates the metabolism of drugs PNAS, September 12, 2006; 103(37): 13565 - 13566. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Isin and F. P. Guengerich Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4 J. Biol. Chem., April 7, 2006; 281(14): 9127 - 9136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Williams, K. Johnson, J. Paulauskis, and J. Cook So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol., March 1, 2006; 46(3): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Engtrakul, R. S. Foti, T. J. Strelevitz, and M. B. Fisher ALTERED AZT (3'-AZIDO-3'-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT Drug Metab. Dispos., November 1, 2005; 33(11): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION Drug Metab. Dispos., November 1, 2005; 33(11): 1729 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Katoh, T. Matsui, H. Okumura, M. Nakajima, M. Nishimura, S. Naito, C. Tateno, K. Yoshizato, and T. Yokoi EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER Drug Metab. Dispos., September 1, 2005; 33(9): 1333 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Bauman, T. C. Goosen, M. Tugnait, V. Peterkin, S. I. Hurst, L. C. Menning, M. Milad, M. H. Court, and J. A. Williams UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., September 1, 2005; 33(9): 1349 - 1354. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
